Author:
Shadle Craig R.,Lee Yih,Majumdar Anup K.,Petty Kevin J.,Gargano Cynthia,Bradstreet Thomas E.,Evans Judith K.,Blum Robert A.
Subject
Pharmacology (medical),Pharmacology
Reference16 articles.
1. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets;Tattersall;Neuropharmacology,2000
2. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group;Navari;N Engl J Med,1999
3. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone;Campos;J Clin Oncol,2001
4. The oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a randomized, double-blind, placebo controlled trial;Poli-Bigelli;Cancer,2003
5. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe;Majumdar;J Clin Pharmacol,2003
Cited by
106 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献